TW200716151A - Polymeric derivative of cytidine metabolic antagonist - Google Patents

Polymeric derivative of cytidine metabolic antagonist

Info

Publication number
TW200716151A
TW200716151A TW095116441A TW95116441A TW200716151A TW 200716151 A TW200716151 A TW 200716151A TW 095116441 A TW095116441 A TW 095116441A TW 95116441 A TW95116441 A TW 95116441A TW 200716151 A TW200716151 A TW 200716151A
Authority
TW
Taiwan
Prior art keywords
metabolic antagonist
cytidine metabolic
cytidine
derivative
polymeric derivative
Prior art date
Application number
TW095116441A
Other languages
English (en)
Other versions
TWI371284B (zh
Inventor
Akira Masuda
Takeshi Onda
Hiroko Mashiba
Keiichirou Yamamoto
Kazutoshi Takashio
Original Assignee
Nippon Kayaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Kk filed Critical Nippon Kayaku Kk
Publication of TW200716151A publication Critical patent/TW200716151A/zh
Application granted granted Critical
Publication of TWI371284B publication Critical patent/TWI371284B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0233—Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/3332—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyethers (AREA)
TW095116441A 2005-05-11 2006-05-09 Polymeric derivative of cytidine metabolic antagonist TW200716151A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005138249 2005-05-11

Publications (2)

Publication Number Publication Date
TW200716151A true TW200716151A (en) 2007-05-01
TWI371284B TWI371284B (zh) 2012-09-01

Family

ID=37396423

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095116441A TW200716151A (en) 2005-05-11 2006-05-09 Polymeric derivative of cytidine metabolic antagonist

Country Status (13)

Country Link
US (1) US7700709B2 (zh)
EP (1) EP1881020B1 (zh)
JP (1) JP5000512B2 (zh)
KR (1) KR101312417B1 (zh)
CN (1) CN101218280B (zh)
AU (1) AU2006245107B2 (zh)
BR (1) BRPI0609095A2 (zh)
CA (1) CA2606939C (zh)
DE (1) DE602006016103D1 (zh)
ES (1) ES2350258T3 (zh)
RU (1) RU2404980C2 (zh)
TW (1) TW200716151A (zh)
WO (1) WO2006120914A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1580216B1 (en) * 2002-10-31 2014-05-14 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
RU2324701C2 (ru) * 2003-03-20 2008-05-20 Ниппон Каяку Кабусики Кайся Мицеллярный препарат, содержащий малорастворимый в воде противораковый агент, содержащее его противораковое средство и новый блок-сополимер
JP4820758B2 (ja) * 2004-09-22 2011-11-24 日本化薬株式会社 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
JP5249016B2 (ja) * 2006-03-28 2013-07-31 日本化薬株式会社 タキサン類の高分子結合体
KR20090009241A (ko) * 2006-05-18 2009-01-22 니폰 가야꾸 가부시끼가이샤 포도필로톡신류의 고분자 결합체
KR20090031597A (ko) * 2006-07-19 2009-03-26 니폰 가야꾸 가부시끼가이샤 콤브레타스타틴류의 고분자 결합체
ES2584840T3 (es) * 2006-10-03 2016-09-29 Nippon Kayaku Kabushiki Kaisha Compuesto de un derivado de resorcinol con un polímero
WO2008056596A1 (fr) * 2006-11-06 2008-05-15 Nippon Kayaku Kabushiki Kaisha Dérivé polymère d'un antagoniste métabolique d'acide nucléique
JP5541594B2 (ja) * 2006-11-07 2014-07-09 ディーエスエム アイピー アセッツ ビー．ブイ． 生体分子部分を含むカルバメート、チオカルバメートまたはカルバミド
JP5548365B2 (ja) * 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
US8703878B2 (en) * 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
WO2009116509A1 (ja) * 2008-03-18 2009-09-24 日本化薬株式会社 生理活性物質の高分子結合体
WO2009136572A1 (ja) 2008-05-08 2009-11-12 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
EP2431403B1 (en) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymer conjugate of bioactive substance having hydroxy group
IT1401360B1 (it) * 2010-05-19 2013-07-18 Lembo Agenti anti-virali e relative composizioni
US8840875B2 (en) 2010-05-19 2014-09-23 Paolo Ferruti Anti-viral agents and compositions thereof
EP2641605B1 (en) * 2010-11-17 2018-03-07 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolism antagonist
WO2012098557A1 (en) * 2011-01-20 2012-07-26 Institute Of Life Sciences Pegylated gemcitabine derivative and process for preparing the same
KR101849142B1 (ko) 2011-09-11 2018-04-16 니폰 가야꾸 가부시끼가이샤 블록 공중합체의 제조방법
WO2014073447A1 (ja) 2012-11-08 2014-05-15 日本化薬株式会社 カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
JP2017160125A (ja) * 2014-08-04 2017-09-14 日本化薬株式会社 核酸代謝拮抗剤が結合したポリアミノ酸誘導体。
RU2732612C2 (ru) * 2015-02-23 2020-09-21 Ниппон Каяку Кабусики Каися Блок-сополимерный конъюгат физиологически активного вещества
US20180334540A1 (en) * 2015-11-18 2018-11-22 Nippon Kayaku Kabushiki Kaisha Polymeric Derivative Of Macrolide Immunosuppressant
EP3400945A4 (en) 2016-01-08 2019-09-11 Nippon Kayaku Kabushiki Kaisha POLYMER DERIVATIVE OF MACROLIDE IMMUNOSUP PRESSIVA
CN106117561B (zh) * 2016-06-27 2020-03-13 中国科学院长春应用化学研究所 一种吉西他滨衍生物及其制备方法
JP6810239B2 (ja) * 2016-07-06 2021-01-06 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 難水溶性薬物を含む高分子ミセル製剤のインビトロ放出試験方法及び評価方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097307A3 (en) * 1982-06-21 1985-01-09 American Hoechst Corporation Thermo-chemically cross-linked poly(p-methylstyrene) and process to obtain it
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
JP3310000B2 (ja) 1990-11-07 2002-07-29 靖久 桜井 水溶性高分子抗癌剤及び薬物担持用担体
JP3268913B2 (ja) * 1992-10-27 2002-03-25 日本化薬株式会社 高分子担体
US5571889A (en) * 1994-05-30 1996-11-05 Mitsui Toatsu Chemicals, Inc. Polymer containing monomer units of chemically modified polyaspartic acids or their salts and process for preparing the same
JPH0848766A (ja) 1994-05-30 1996-02-20 Mitsui Toatsu Chem Inc 重合体及びその製造方法
JP2694923B2 (ja) 1995-08-21 1997-12-24 科学技術振興事業団 水溶性高分子化医薬製剤
JPH11279083A (ja) 1998-03-30 1999-10-12 Nippon Kayaku Co Ltd 可溶化剤
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
AU2002251988A1 (en) * 2001-02-20 2002-09-04 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
EP1594482A1 (en) * 2003-03-26 2005-11-16 LTT Bio-Pharma Co., Ltd. Intravenous nanoparticles for targeting drug delivery and sustained drug release
ES2629696T3 (es) * 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
WO2005030835A1 (ja) * 2003-09-25 2005-04-07 Terumo Kabushiki Kaisha ポリエチレングリコール誘導体及びこれを膜構成成分とする薬物担体
AU2004297126B2 (en) * 2003-12-10 2010-11-25 Toudai Tlo, Ltd. Coordination complex of diaminocyclohexaneplatinum(II) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same

Also Published As

Publication number Publication date
CN101218280A (zh) 2008-07-09
CA2606939A1 (en) 2006-11-16
ES2350258T3 (es) 2011-01-20
AU2006245107A1 (en) 2006-11-16
DE602006016103D1 (de) 2010-09-23
TWI371284B (zh) 2012-09-01
CA2606939C (en) 2013-09-03
EP1881020A1 (en) 2008-01-23
BRPI0609095A2 (pt) 2010-02-17
US7700709B2 (en) 2010-04-20
KR20080013883A (ko) 2008-02-13
EP1881020A4 (en) 2009-09-02
KR101312417B1 (ko) 2013-09-27
CN101218280B (zh) 2012-06-27
RU2007145718A (ru) 2009-06-20
EP1881020B1 (en) 2010-08-11
WO2006120914A1 (ja) 2006-11-16
RU2404980C2 (ru) 2010-11-27
JP5000512B2 (ja) 2012-08-15
US20090012252A1 (en) 2009-01-08
JPWO2006120914A1 (ja) 2008-12-18
AU2006245107B2 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
TW200716151A (en) Polymeric derivative of cytidine metabolic antagonist
JO3492B1 (ar) تركيبات صيدلانية من مضاد مستقبل أنجيوتنسين ومثبط nep
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
IL197923A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
IL197924A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
NZ588839A (en) Multivalent vla-4 antagonists comprising polyethylene glycol moieties
MX2009007145A (es) Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
IL194429A0 (en) Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
PL1909845T3 (pl) Amid N,N-bis-(2-hydroksyetylo)glyciny jako łącznik w prolekach sprzężonych z polimerem
WO2004084950A3 (en) Cell targeting methods and compositions
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
DK2121713T3 (da) Oligosaccharider, omfattende en aminooxygruppe, og konjugater deraf
IL189781A0 (en) Sulphonylpyrrole hydrochloride salts and pharmaceutical compositions containing the same
ATE414725T1 (de) Amphotere ethylmethacrylat-copolymere und deren verwendung
TW200735660A (en) Camera mount
BRPI0716643A2 (pt) amidas terapêuticas e compostos relacionados
IN2012DN02609A (zh)
MX2010004110A (es) Formulacion para mejorar la funcion gastrointestinal.
WO2007005941A3 (en) Liver targeted conjugates
MX336410B (es) Materiales polimericos.
SI1876169T1 (sl) N-acil amin, ki vsebuje fenil in derivati aminokislin, metode za njihovo izdelavo, farmacevtski sestavek in njihova uporaba
TW200735875A (en) Pharmaceutical compositions
EA200870148A1 (ru) Производные сулиндака, их применение и получение
ZA200604874B (en) Pharmaceutical compositions
AP1994A (en) An antimycobacterial pharmaceutical composition

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees